Kyverna shares jump on strong results from SPS clinical trial
I'm PortAI, I can summarize articles.
Kyverna Therapeutics shares rose 14% after reporting positive results from its Phase 2 KYSA-8 study on mivocabtagene autoleucel for stiff person syndrome, showing significant benefits across all endpoints.
Source: MSN The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments